Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

1.1K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.1K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

1.7K
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
1.7K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Periorificial Dermatitis, Rosacea, and Idiopathic Aseptic Facial Granuloma in Children.

Pediatric clinics of North America·2026
Same author

Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patterns.

Haematologica·2026
Same author

Innovative approaches for managing relapsed or refractory peripheral T-cell lymphoma.

Expert opinion on pharmacotherapy·2026
Same author

Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

QIM26-301: Implementation of a Same-Day Cancer Care Clinic at an Academic Medical Center.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

BIO26-035: Validation of an Electronic Health Record Phenotype for Advanced Solid Cancer Across Five University of California Health Systems.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Related Experiment Video

Updated: Feb 22, 2026

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

12.3K

DCOne as an Allogeneic Cell-based Vaccine for Multiple Myeloma.

Rebecca Karp Leaf1, Dina Stroopinsky, Athalia R Pyzer

  • 1*Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, MA †DCPrime BV, Leiden, The Netherlands.

Journal of Immunotherapy (Hagerstown, Md. : 1997)
|September 30, 2017
PubMed
Summary
This summary is machine-generated.

This study shows that the DCOne allogeneic cellular vaccine can activate immune responses against multiple myeloma (MM). It stimulates T cells to recognize and kill autologous MM cells, offering a potential new cancer vaccine therapy.

More Related Videos

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.8K
Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

15.0K

Related Experiment Videos

Last Updated: Feb 22, 2026

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

12.3K
Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.8K
Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

15.0K

Area of Science:

  • Immunology
  • Oncology
  • Vaccinology

Background:

  • Multiple myeloma (MM) involves immune dysregulation and an immunosuppressive environment.
  • Cancer vaccines targeting immune suppression are a promising therapeutic strategy for MM.

Purpose of the Study:

  • To investigate the potential of an allogeneic cellular vaccine (DCOne) to generate anti-MM immune responses.
  • To assess DCOne's ability to overcome immune suppression in the MM tumor microenvironment.

Main Methods:

  • DCOne vaccine, derived from a dendritic cell line expressing MM-associated antigens, was used.
  • Peripheral blood mononuclear cells (PBMCs) from MM patients were cocultured with DCOne.
  • Immune cell activation (CD8 T cells, interferon-γ, perforin) and cytotoxic activity against autologous MM cells were analyzed.

Main Results:

  • DCOne vaccine antigens were transferred via extracellular vesicles to antigen-presenting cells, stimulating T cells.
  • Coculture with DCOne led to expansion of activated CD8 T cells in MM patient PBMCs.
  • DCOne facilitated the induction of cytotoxic T-lymphocyte-mediated killing of autologous MM cells.

Conclusions:

  • The allogeneic DCOne vaccine can induce T-cell activation and myeloma-specific immunity.
  • DCOne promotes immunity through cross-presentation of antigens by native antigen-presenting cells.
  • This vaccine strategy holds potential for treating multiple myeloma by restoring anti-tumor immunity.